Maynard Um
-
-
-
-
-
-
-
Canaccord Starts BridgeBio Oncology Therapeutics, In (BBOT) at Buy
-
-
-
-
-
-
-
Oppenheimer on BridgeBio Oncology Therapeutics, In (BBOT): 'We think the lack of idiosyncratic toxicity is particularly notable for BBO-10203'
-
-
-
-
-
-
-
Oppenheimer Starts BridgeBio Oncology Therapeutics, In (BBOT) at Outperform
-
-
-
-
466,297 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


